DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis
USA - NASDAQ:DVAX - US2681582019 - Common Stock
9.41 USD
-0.33 (-3.39%)
9.42 USD
+0.01 (+0.11%)
DVAX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year DVAX was profitable.
DVAX had a positive operating cash flow in the past year.
In multiple years DVAX reported negative net income over the last 5 years.
Of the past 5 years DVAX 4 years had a positive operating cash flow.
1.2 Ratios
DVAX has a better Return On Assets (-5.74%) than 87.08% of its industry peers.
Looking at the Return On Equity, with a value of -10.67%, DVAX belongs to the top of the industry, outperforming 88.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROIC | N/A |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Profit Margin has declined in the last couple of years.
With an excellent Gross Margin value of 82.83%, DVAX belongs to the best of the industry, outperforming 86.16% of the companies in the same industry.
DVAX's Gross Margin has improved in the last couple of years.
DVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
DVAX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DVAX is higher compared to a year ago.
2.2 Solvency
DVAX has an Altman-Z score of 1.28. This is a bad value and indicates that DVAX is not financially healthy and even has some risk of bankruptcy.
DVAX has a better Altman-Z score (1.28) than 63.65% of its industry peers.
The Debt to FCF ratio of DVAX is 3.95, which is a good value as it means it would take DVAX, 3.95 years of fcf income to pay off all of its debts.
DVAX has a better Debt to FCF ratio (3.95) than 93.36% of its industry peers.
DVAX has a Debt/Equity ratio of 0.53. This is a neutral value indicating DVAX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, DVAX is doing worse than 73.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Altman-Z | 1.28 |
ROIC/WACCN/A
WACC9.2%
2.3 Liquidity
A Current Ratio of 6.65 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a better Current ratio (6.65) than 66.61% of its industry peers.
DVAX has a Quick Ratio of 6.01. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DVAX (6.01) is better than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 186.36% over the past year.
Measured over the past years, DVAX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.10% on average per year.
DVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.67%.
DVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.10% yearly.
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
3.2 Future
DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.55% yearly.
Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 15.25% on average per year.
EPS Next Y-336.58%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.41 indicates a quite expensive valuation of DVAX.
DVAX's Price/Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 92.62% of the companies in the same industry.
DVAX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.30.
The Price/Forward Earnings ratio is 19.02, which indicates a rather expensive current valuation of DVAX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DVAX indicates a rather cheap valuation: DVAX is cheaper than 92.80% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.73. DVAX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.41 | ||
| Fwd PE | 19.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaply inside the industry as 92.44% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DVAX indicates a rather cheap valuation: DVAX is cheaper than 95.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.7 | ||
| EV/EBITDA | 26.3 |
4.3 Compensation for Growth
A more expensive valuation may be justified as DVAX's earnings are expected to grow with 58.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.78%
EPS Next 3Y58.55%
5. Dividend
5.1 Amount
DVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.41
-0.33 (-3.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners108.45%
Inst Owner Change-5.85%
Ins Owners0.55%
Ins Owner Change-12.01%
Market Cap1.10B
Analysts80
Price Target24.48 (160.15%)
Short Float %11.91%
Short Ratio8.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.28%
Min EPS beat(2)-86.66%
Max EPS beat(2)30.1%
EPS beat(4)3
Avg EPS beat(4)-9.07%
Min EPS beat(4)-86.66%
Max EPS beat(4)30.1%
EPS beat(8)6
Avg EPS beat(8)79.21%
EPS beat(12)9
Avg EPS beat(12)63.09%
EPS beat(16)10
Avg EPS beat(16)25.23%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-3.96%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)7.97%
Revenue beat(8)3
Avg Revenue beat(8)-0.53%
Revenue beat(12)7
Avg Revenue beat(12)3.41%
Revenue beat(16)9
Avg Revenue beat(16)9.62%
PT rev (1m)0.76%
PT rev (3m)0.76%
EPS NQ rev (1m)-9.75%
EPS NQ rev (3m)-14.09%
EPS NY rev (1m)-1.77%
EPS NY rev (3m)-451.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)1.69%
Revenue NY rev (3m)1.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.41 | ||
| Fwd PE | 19.02 | ||
| P/S | 3.49 | ||
| P/FCF | 16.7 | ||
| P/OCF | 14.47 | ||
| P/B | 2.23 | ||
| P/tB | 2.24 | ||
| EV/EBITDA | 26.3 |
EPS(TTM)0.32
EY3.4%
EPS(NY)0.49
Fwd EY5.26%
FCF(TTM)0.56
FCFY5.99%
OCF(TTM)0.65
OCFY6.91%
SpS2.7
BVpS4.21
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% | ||
| FCFM | 20.89% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Debt/EBITDA | 35.01 | ||
| Cap/Depr | 124.44% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1023.9% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 1.28 |
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-336.58%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
EBIT growth 1Y94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year356.6%
EBIT Next 3Y104.13%
EBIT Next 5YN/A
FCF growth 1Y-55.18%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-49.89%
OCF growth 3Y-41.69%
OCF growth 5YN/A